Custom Solutions for IgA Nephropathy (IgAN) Animal Model Development

Download

IgA nephropathy (IgAN) is one of the most common primary glomerulonephritides globally and a major driver of progressive kidney failure leading to end-stage renal disease (ESRD). Characterized by complex multi-hit immunopathological mechanisms, the disease presents significant challenges in therapeutic intervention. Preclinical research relies heavily on robust, clinically relevant animal models that mimic human pathophysiology to elucidate underlying mechanisms and evaluate promising therapeutic candidates.

At Protheragen, we deliver end-to-end preclinical solutions spanning diagnostics development, therapeutic development, disease model development, and preclinical safety and efficacy evaluations. We offer a comprehensive suite of IgA nephropathy (IgAN) animal models designed to faithfully simulate human pathophysiological features—such as galactose-deficient IgA1 (Gd-IgA1) immune complex deposition, complement activation, mesangial proliferation, and renal dysfunction—empowering global biopharmaceutical partners to de-risk and accelerate their translational pipelines.

Overview of IgA Nephropathy (IgAN) Animal Models

IgA nephropathy (IgAN) is driven by a complex multi-step cascade, commonly described by the "Four-Hit" hypothesis. This pathway begins with elevated circulating levels of galactose-deficient IgA1 (Gd-IgA1) (Hit 1), followed by the generation of specific autoantibodies targeting these aberrantly glycosylated IgA1 molecules (Hit 2). The resulting immune complexes (Hit 3) deposit in the glomerular mesangium, triggering complement activation, inflammatory cell infiltration, and progressive tissue damage (Hit 4). Because laboratory animals do not naturally develop human-like IgAN, tailored in vivo models—including genetically engineered humanized strains and induced immune complex models—are essential tools to recapitulate key pathological events and validate novel therapeutic strategies.

Fig 1. The pathogenesis of IgA nephropathy (IgAN): the four-hit theory. (Fan, Yitao, et al., 2024)

Applications of IgA Nephropathy (IgAN) Animal Models

IgAN animal models play a vital role in bridging basic disease mechanisms with clinical drug discovery, providing controlled in vivo environments to evaluate multi-target therapeutic modalities.

Workflow for IgA Nephropathy (IgAN) Animal Model Development

Protheragen employs a standardized, rigorous workflow to ensure the successful construction, validation, and delivery of both genetically engineered and induced IgAN animal models:

• Consultation & Strategy Design: Collaborative assessment of client research objectives, target mechanisms, and regulatory needs to select or engineer the optimal animal strain and strategy.
• Model Engineering / Induction:
  • Genetically Engineered Models: Execution of precise gene modification strategies (e.g., CRISPR/Cas9 site-specific knock-in/knockout) to generate target humanized or mutated lines.
  • Induced Models: Administration of specialized induction agents (e.g., pre-formed Gd-IgA1/IgG immune complexes or multi-factor regimens like BSA/LPS/CCl4) using optimized dosing protocols.
• Phenotypic & Biomarker Validation: Multi-dimensional verification of disease phenotypes via gene expression (RT-qPCR), protein expression (ELISA/Western blot), renal histopathology (PAS staining), immunofluorescence (IgA/IgG/C3 deposition), and urinalysis (UPCR, hematuria, albuminuria).
• Study Execution & Reporting: High-fidelity execution of downstream pharmacodynamic and efficacy protocols followed by delivery of comprehensive, submission-ready data packages.

Available IgA Nephropathy (IgAN) Animal Models

We offer a diverse portfolio of fully validated genetically engineered and induced models catering to various mechanism-of-action studies:

Integrated Preclinical Research Services for IgA Nephropathy (IgAN)

Beyond animal model development, Protheragen provides a one-stop preclinical research platform to fully characterize the safety, efficacy, and pharmacological profiles of novel IgAN drug candidates:

Case Study 01-Gd-IgA1/IgG Immune Complex-induced Mouse Model

To construct the Gd-IgA1/IgG immune complex-induced mouse model, soluble immune complexes prepared in vitro from human polymeric Gd-IgA1 and IgAN patient-derived autoantibody IgG were intravenously injected into athymic BALB/c nude mice on three consecutive days. Comprehensive downstream evaluations—including glomerular deposits staining analysis and albuminuria & hematuria detection—confirmed the successful establishment of the model, marked by prominent mesangial deposition of IgA, IgG, and complement C3 alongside significantly elevated urinary protein and red blood cell levels compared to controls.

Fig 2. Albuminuria and hematuria were measured in six groups of mice (n = 6 per group) to evaluate renal function. I: Gd-IgA1 + IgG from sera of IgAN patients; II: Gd-IgA1 + IgG from sera of healthy controls; III: Polymeric Gd-IgA1; IV: Monomeric Gd-IgA1; V: IgA1 from healthy controls; VI: PBS (negative control). Data are presented as individual data points for each mouse, along with the mean ± standard deviation (SD).

Having validated this immunopathological phenotype, the model serves as a robust platform for in vivo efficacy and pharmacodynamic testing. Daily oral administration of a novel therapeutic candidate in this protocol effectively attenuated immune complex-induced glomerular hypercellularity, downregulated Ki-67 proliferation markers, and normalized key disease-associated hub genes (such as Tgtp1), demonstrating high translational value for candidate evaluation.

Fig 3. Quantification of glomerular cellular proliferation in engineered immune complex (EIC)-induced IgAN mice treated with candidate drug across four experimental groups: (1) PBS + Vehicle, (2) EIC + Vehicle, (3) EIC + Candidate drug 60 mg/kg, and (4) EIC + Candidate drug 120 mg/kg. (A) Count of total nuclei per glomerulus; (B) Percentage of Ki-67-positive proliferative glomeruli. (*P < 0.0001 vs. EIC group).

Case Study 02-huIgA1/IGHA1 Mouse Model

The huIgA1 mouse model was established using a gene-targeting strategy that inserts the human IGHA1 constant region sequence into the locus between the mouse IgM enhancer (Eμ) and IgM constant region (Cμ)—replacing the murine Sμ region—and was successfully validated by RT-qPCR and serum ELISA showing robust human IGHA1 mRNA expression in spleen and kidney tissues alongside high circulating levels of human IgA1 protein compared to wild-type controls, providing an ideal humanized platform for evaluating B-cell biology, IgA formation, and human IgA1-targeted therapeutics.

Fig 4. Validation of human IgA1 expression in huIgA1 mice (n = 3). (A) RT-qPCR analysis of human IGHA1 transcript levels in spleen and kidney tissues of 7–8-week-old wild-type (WT) and huIgA1 mice (both sexes). (B) ELISA quantification of circulating human IgA1 protein levels in serum from 8-week-old WT and huIgA1 mice.

Case Study 03-B6-Cd14-hCD89/hIGHA1 Mouse Model

The dual-humanized B6-Cd14-hFCAR(CD89)/hIGHA1 mouse model—generated by crossing B6-Cd14-hFCAR(CD89) mice with B6-hIGHA1 mice—exhibits spontaneous, progressive IgAN-like pathology, as evidenced by long-term evaluations showing significantly elevated urinary protein/creatinine ratio (UPCR) levels in humanized females compared to wild-type controls, along with a more severe disease phenotype in females marked by reduced 30-week survival rates (85.7% vs. 91.8% in males).

Fig 5. (A) Spontaneous mortality in B6-Cd14-hCD89/hIGHA1 mice showed a higher rate of mortality for females. (B) Urine was collected for kidney functional analysis from 7 to 33-week-old female B6 and B6-Cd14-FCAR(CD89)/hIGHA1 mice (KI/KI; KI/KI) respectively.

Case Study 04-Cd11b-hCD89 (FCAR) Mouse Model

The Cd11b-hCD89 (FCAR) knock-in model—created by inserting the human FCAR (CD89) coding sequence downstream of the mouse Cd11b (Itgam) stop codon via an Itgam-IRES-hCD89 vector—enables myeloid-specific human CD89 expression, which was successfully validated by RT-qPCR showing robust human FCAR mRNA expression in lymphoid tissues (thymus and spleen) and flow cytometry confirming that over 8% of mCD45+ peritoneal wash leukocytes co-express mCd11b and human CD89 protein without gender bias, establishing a robust platform for studying CD89-mediated IgA immunity and therapeutic interventions.

Fig 6. (A) RT-qPCR analysis of human FCAR mRNA expression in wild-type (WT) and heterozygous Cd11b-hCD89 (FCAR) knock-in (KI/+) mice; (B) Detection of human CD89 protein expression in peritoneal cells from WT and KI/+ mice (6 weeks old, n=3).

Case Study 05-BSA/LPS/CCl4-induced IgAN Rat Model

The BSA/LPS/CCl4-induced IgAN rat model—established in eight-week-old male Sprague-Dawley rats via unilateral nephrectomy paired with a 10-week multi-agent induction protocol (oral BSA, intraperitoneal CCl4, and LPS)—exhibits severe functional renal damage characterized by marked elevations in 24-hour urinary albumin (ALB), elevated urinary albumin-to-creatinine ratio (UACR), and extensive mesangial IgA/C3 immune deposits, which were significantly attenuated following a 6-week treatment with a test compound to validate the model's sensitivity for drug screening.

Fig 7. Urine albumin (ALB, A) and urine albumin-to-creatinine ratio (UACR, B) along with glomerular IgA (C) and C3 (D) immune deposition levels across different treatment groups. (*P < 0.05, **P < 0.01, ***P < 0.001 vs. G2 Model group).

Why Choose Us?

• Deep Scientific Expertise: Driven by a multidisciplinary team of veteran researchers with specialized experience in nephrology, immunology, and rare diseases.
• Integrated End-to-End Solutions: Offering seamless transitions from target identification and custom model development to complex in vivo pharmacology and regulatory safety assessments.
• Cutting-Edge Platforms: Utilizing advanced CRISPR/Cas9 genetic engineering, humanized animal lines, and state-of-the-art imaging and omics facilities.
• Tailored Study Designs: Providing highly customizable study protocols engineered to match the specific pharmacological profiles, timelines, and strategic goals of your pipeline.

Contact Us

At Protheragen, we offer a comprehensive portfolio of IgA nephropathy (IgAN) disease models to accelerate your translational research and drug discovery pipeline. Our offerings cover genetically engineered humanized mouse strains as well as robust induced models. These rigorously validated models reliably recapitulate human IgAN pathobiology—from immune complex formation and mesangial deposition to renal functional decline—providing an ideal platform for target validation, biomarker discovery, and preclinical efficacy testing. Contact us today to discuss your IgAN research needs and explore how our validated disease models can streamline your drug development process.

References

1. Fan, Yitao, et al. "Advancements in understanding the role of intestinal dysbacteriosis mediated mucosal immunity in IgA nephropathy." BMC nephrology 25.1 (2024): 203.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Rare Disease Diagnostics Development
• Rare Disease Therapeutics Development
• Drug Repurposing Service
• Rare Disease Model Development Services
• Drug Safety Evaluation Services
• Pharmacokinetics Services